{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:25:01Z","timestamp":1792592701538,"version":"4.5.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit of therapeutic heparin in hospitalized noncritically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic-dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research have improved care of hospitalized patients with COVID-19.<\/jats:p>","DOI":"10.1182\/blood.2021014527","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T18:53:57Z","timestamp":1654196037000},"page":"809-814","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Anticoagulation in hospitalized patients with COVID-19"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1171-0548","authenticated-orcid":false,"given":"Lisa","family":"Baumann Kreuziger","sequence":"first","affiliation":[{"name":"1Department of Medicine Medical College of Wisconsin, Blood Research Institute, Versiti, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1220-0301","authenticated-orcid":false,"given":"Michelle","family":"Sholzberg","sequence":"additional","affiliation":[{"name":"2Department of Medicine and"},{"name":"3Department of Laboratory Medicine and Pathobiology, St. Michael\u2019s Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, ON, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7871-6143","authenticated-orcid":false,"given":"Mary","family":"Cushman","sequence":"additional","affiliation":[{"name":"4Department of Medicine and"},{"name":"5Department of Pathology & Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2022082515223736200_B1","author":"Johns Hopkins University"},{"key":"2022082515223736200_B2","author":"Our World in Data"},{"issue":"22","key":"2022082515223736200_B3","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv."},{"issue":"6","key":"2022082515223736200_B4","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/jth.14830","article-title":"Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia","volume":"18","author":"Cui","year":"2020","journal-title":"J Thromb Haemost."},{"issue":"4","key":"2022082515223736200_B5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.2020006520","article-title":"COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection","volume":"136","author":"Al-Samkari","year":"2020","journal-title":"Blood."},{"issue":"7","key":"2022082515223736200_B6","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/rth2.12439","article-title":"Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis","volume":"4","author":"Nopp","year":"2020","journal-title":"Res Pract Thromb Haemost."},{"issue":"12","key":"2022082515223736200_B7","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00011-020-01401-6","article-title":"The coagulopathy, endotheliopathy, and vasculitis of COVID-19","volume":"69","author":"Iba","year":"2020","journal-title":"Inflamm Res."},{"issue":"5","key":"2022082515223736200_B8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/rth2.12372","article-title":"A proposal for staging COVID-19 coagulopathy","volume":"4","author":"Thachil","year":"2020","journal-title":"Res Pract Thromb Haemost."},{"issue":"4","key":"2022082515223736200_B9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M20-2003","article-title":"Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study","volume":"173","author":"Wichmann","year":"2020","journal-title":"Ann Intern Med."},{"issue":"1","key":"2022082515223736200_B10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12959-020-00256-5","article-title":"Autopsy and statistical evidence of disturbed hemostasis progress in COVID-19: medical records from 407 patients","volume":"19","author":"Jiang","year":"2021","journal-title":"Thromb J."},{"issue":"9","key":"2022082515223736200_B11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N Engl J Med."},{"issue":"2400","key":"2022082515223736200_B12","doi-asserted-by":"crossref","first-page":"n2400","DOI":"10.1136\/bmj.n2400","article-title":"Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial","volume":"375","author":"Sholzberg","year":"2021","journal-title":"BMJ."},{"issue":"12","key":"2022082515223736200_B13","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID Randomized Clinical Trial","volume":"181","author":"Spyropoulos","year":"2021","journal-title":"JAMA Intern Med."},{"issue":"8","key":"2022082515223736200_B14","doi-asserted-by":"crossref","first-page":"e12638","DOI":"10.1002\/rth2.12638","article-title":"Randomized trials of therapeutic heparin for COVID-19: a meta-analysis","volume":"5","author":"Sholzberg","year":"2021","journal-title":"Res Pract Thromb Haemost."},{"issue":"7","key":"2022082515223736200_B15","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/CCM.0000000000003746","article-title":"Reporting of organ support outcomes in septic shock randomized controlled trials: a methodologic review: the Sepsis Organ Support Study","volume":"47","author":"Bourcier","year":"2019","journal-title":"Crit Care Med."},{"issue":"5","key":"2022082515223736200_B16","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00134-020-05934-6","article-title":"Contemporary strategies to improve clinical trial design for critical care research: insights from the First Critical Care Clinical Trialists Workshop","volume":"46","author":"Harhay","year":"2020","journal-title":"Intensive Care Med."},{"issue":"10291","key":"2022082515223736200_B17","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"Lopes","year":"2021","journal-title":"Lancet."},{"issue":"16","key":"2022082515223736200_B18","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/jama.2021.4152","article-title":"Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION Randomized Clinical Trial","volume":"325","author":"Sadeghipour","year":"2021","journal-title":"JAMA."},{"issue":"9","key":"2022082515223736200_B19","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/jth.15450","article-title":"Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial","volume":"19","author":"Perepu","year":"2021","journal-title":"J Thromb Haemost."},{"issue":"9","key":"2022082515223736200_B20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with Covid-19","volume":"385","author":"Goligher","year":"2021","journal-title":"N Engl J Med."},{"key":"2022082515223736200_B21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.thromres.2020.09.026","article-title":"Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID)","volume":"196","author":"Lemos","year":"2020","journal-title":"Thromb Res."},{"key":"2022082515223736200_B22","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvac010","article-title":"Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens with COVID-19","author":"Ortega-Paz","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"2","key":"2022082515223736200_B23","doi-asserted-by":"crossref","first-page":"e12666","DOI":"10.1002\/rth2.12666","article-title":"COVID-19 and venous thromboembolism: a narrative review","volume":"6","author":"Angelini","year":"2022","journal-title":"Res Pract Thromb Haemost."},{"issue":"11","key":"2022082515223736200_B24","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1182\/blood.2020008086","article-title":"Postdischarge venous thromboembolism following hospital admission with COVID-19","volume":"136","author":"Roberts","year":"2020","journal-title":"Blood."},{"issue":"10319","key":"2022082515223736200_B25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial","volume":"399","author":"Ramacciotti","year":"2022","journal-title":"Lancet."},{"issue":"5","key":"2022082515223736200_B26","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jth.14810","article-title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"J Thromb Haemost."},{"issue":"1","key":"2022082515223736200_B27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11239-020-02138-z","article-title":"Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum","volume":"50","author":"Barnes","year":"2020","journal-title":"J Thromb Thrombolysis."},{"issue":"3","key":"2022082515223736200_B28","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/bloodadvances.2020003763","article-title":"American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19","volume":"5","author":"Cuker","year":"2021","journal-title":"Blood Adv."},{"issue":"3","key":"2022082515223736200_B29","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.chest.2020.05.559","article-title":"Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST Guideline and Expert Panel Report","volume":"158","author":"Moores","year":"2020","journal-title":"Chest."},{"key":"2022082515223736200_B30","author":"International Society on Thrombosis and Haemostasis"},{"key":"2022082515223736200_B31","article-title":"Living guidance for clinical management of COVID-19","author":"World Health Organization"},{"key":"2022082515223736200_B32","article-title":"NICE COVID-19 management","author":"The National Institute for Health and Care Excellence (NICE)"},{"key":"2022082515223736200_B33","article-title":"ASH guidelines on use of anticoagulation in patients with COVID-19","author":"American Society of Hematology"},{"key":"2022082515223736200_B34","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2022.02.006","article-title":"Thromboprophylaxis in patients with COVID-19. A brief update to the CHEST Guideline and Expert Panel Report","volume":"162","author":"Moores","year":"2022","journal-title":"Chest."},{"issue":"7","key":"2022082515223736200_B35","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/hq0701.093686","article-title":"Mechanism of action and pharmacology of unfractionated heparin","volume":"21","author":"Hirsh","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"4","key":"2022082515223736200_B36","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/rth2.12353","article-title":"Using heparin molecules to manage COVID-2019","volume":"4","author":"Liu","year":"2020","journal-title":"Res Pract Thromb Haemost."},{"key":"2022082515223736200_B37","doi-asserted-by":"crossref","first-page":"575047","DOI":"10.3389\/fimmu.2020.575047","article-title":"Increased plasma heparanase activity in COVID-19 patients","volume":"11","author":"Buijsers","year":"2020","journal-title":"Front Immunol."},{"key":"2022082515223736200_B38","doi-asserted-by":"crossref","first-page":"102969","DOI":"10.1016\/j.ebiom.2020.102969","article-title":"Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients","volume":"59","author":"Buijsers","year":"2020","journal-title":"EBioMedicine."},{"issue":"5","key":"2022082515223736200_B39","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.4049\/jimmunol.175.5.3377","article-title":"Local bradykinin formation is controlled by glycosaminoglycans","volume":"175","author":"Renn\u00e9","year":"2005","journal-title":"J Immunol."},{"issue":"5","key":"2022082515223736200_B40","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1046\/j.1365-2222.1998.00283.x","article-title":"Regulation of interleukin-8 binding and function by heparin and alpha2-macroglobulin","volume":"28","author":"Ramdin","year":"1998","journal-title":"Clin Exp Allergy."},{"issue":"12","key":"2022082515223736200_B41","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1055\/s-0040-1721319","article-title":"Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the Spike S1 receptor-binding domain with heparin","volume":"120","author":"Mycroft-West","year":"2020","journal-title":"Thromb Haemost."},{"key":"2022082515223736200_B42","article-title":"2019 COVID-19 treatment guidelines","author":"NIH Coronavirus Disease"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/8\/809\/1916670\/bloodbld2021014527c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/8\/809\/1916670\/bloodbld2021014527c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T15:24:51Z","timestamp":1661441091000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/8\/809\/485455\/Anticoagulation-in-hospitalized-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014527","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}